TTK Healthcare Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2025.
TTKHLTCARE · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.9 pts less than Nifty Microcap 250 and 3.9 pts less than its Diversified peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
TTK Healthcare Limited reported its Q1 FY26 results with revenue from operations at Rs. 22,642.98 lakhs, up about 8.9% year-on-year from Rs. 20,790.21 lakhs in Q1 FY25, and up roughly 19% sequentially from Q4 FY25. Pre-exceptional profit before tax stood at Rs. 1,765.35 lakhs versus Rs. 2,102.38 lakhs in the year-ago quarter, a decline of about 16%. Profit after tax came in at Rs. 1,299.94 lakhs compared to Rs. 3,157.51 lakhs in Q1 FY25, which was flattered by a one-time gain of Rs. 1,977.05 lakhs from the sale of leasehold land at Mahindra World City, Chennai. Basic EPS for the quarter was Rs. 9.20 against Rs. 22.35 in Q1 FY25. The business is diversified across Animal Welfare, Consumer Products, Medical Devices, Protective Devices, and Foods segments, with Foods and Consumer Products showing strong growth. Statutory auditors PKF Sridhar & Santhanam LLP issued a clean limited review report with no qualifications.
The sharp YoY drop in headline profit and EPS is mostly an optical effect from the prior year's one-time land sale gain, so the headline numbers should be read cautiously. On a like-for-like pre-exceptional basis, core earnings have softened modestly, and rising other expenses (up about 17% YoY against 9% revenue growth) hint at some margin pressure. The results are broadly neutral for shareholders, with no negative audit flags and continued topline growth.